Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
– FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study –
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
